Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Elite PharmaceuticalsELTP +1.66%60 Net Current Asset Value is $0.07 as of Mar. 2026, which is 99% below its 10-year median of 9.97. GuruFocus rates ELTP with a GF Score™ of 60/100 and a GF Value™ of $0.57 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 608 Drug Manufacturers companies, Elite Pharmaceuticals ranks better than 52.63% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
Elite Pharmaceuticals's net current asset value per share for the quarter that ended in Mar. 2026 was $0.07.
The historical rank and industry rank for Elite Pharmaceuticals's Net Current Asset Value or its related term are showing as below:
ELTP'
s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.9 Med: 9.97 Max: 43.5
Current: 5.41
During the past 13 years, the highest Price-to-Net-Current-Asset-Value Ratio of Elite Pharmaceuticals was 43.50. The lowest was 2.90. And the median was 9.97.
ELTP's Price-to-Net-Current-Asset-Value is ranked better than 52.63% of 608
companies
in the Drug Manufacturers industry
Industry Median: 5.71
vs ELTP: 5.41
Elite Pharmaceuticals (OTCPK:ELTP) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
Elite Pharmaceuticals Net Current Asset Value Related Terms
Elite Pharmaceuticals Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for Elite Pharmaceuticals's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Elite Pharmaceuticals Net Current Asset Value Chart
ELTP vs EOLS, EBS, AQST: Net Current Asset Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Elite Pharmaceuticals's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elite Pharmaceuticals Price-to-Net-Current-Asset-Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Elite Pharmaceuticals's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where Elite Pharmaceuticals's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of $0.07 mean?
Elite Pharmaceuticals (ELTP) has a Net Current Asset Value of $0.07 as of Mar. 2026. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Elite Pharmaceuticals and its competitors. This is 99% below median its historical median of 9.97. Over the past decade, Elite Pharmaceuticals' Net Current Asset Value has ranged from 2.90 to 43.50. According to the industry distribution chart, Elite Pharmaceuticals ranks #288 out of 608 companies in the Drug Manufacturers industry, placing it in the top 47.4%.
Is Elite Pharmaceuticals' Net Current Asset Value too high?
Elite Pharmaceuticals' current Net Current Asset Value of $0.07 is 99% below median its 10-year median of 9.97. Over the past 10 years, this metric has ranged from a low of 2.90 to a high of 43.50. The Drug Manufacturers industry median Net Current Asset Value is 5.71. Elite Pharmaceuticals' value of $0.07 is 98.8% below this industry median. Based on the distribution chart, Elite Pharmaceuticals ranks #288 out of 608 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Elite Pharmaceuticals has a GF Score™ of 60/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Elite Pharmaceuticals' Net Current Asset Value compare to EOLS and EBS?
According to the Drug Manufacturers industry distribution chart, Elite Pharmaceuticals ranks #288 out of 608 companies for Net Current Asset Value. This puts Elite Pharmaceuticals in the upper half of its industry. The industry median Net Current Asset Value is 5.71. Elite Pharmaceuticals' value of $0.07 is 98.8% below this benchmark. Historically, Elite Pharmaceuticals' own Net Current Asset Value has ranged from 2.90 to 43.50 over the past decade. While the company's 10-year median is 9.97 vs. the industry median of 5.71, Elite Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Drug Manufacturers company?
The median Net Current Asset Value among Drug Manufacturers companies is 5.71, based on 608 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Elite Pharmaceuticals's current Net Current Asset Value of $0.07 is 98.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on Elite Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Net Current Asset Value is 5.71 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Elite Pharmaceuticals's current Net Current Asset Value is $0.07, which is 99% below median its own 10-year median of 9.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Elite Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Elite Pharmaceuticals (ELTP) is currently considered Possible Value Trap. The stock's GF Value™ is $0.57, compared to a current price of $0.38 — trading 33.5% below its estimated fair value. The current Net Current Asset Value is $0.07, which is 99% below median its 10-year median of 9.97 and 98.8% below the Drug Manufacturers industry median of 5.71. Elite Pharmaceuticals' overall GF Score™ is 60/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For Elite Pharmaceuticals (ELTP), the current Net Current Asset Value is $0.07 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Elite Pharmaceuticals (ELTP) Overvalued in 2026?
Based on GuruFocus' analysis, Elite Pharmaceuticals stock appears to be undervalued.
The current stock price of $0.38 is trading 33.5% below its estimated GF Value™ of $0.57.
GuruFocus considers Elite Pharmaceuticals to be Possible Value Trap.
Key valuation signals for ELTP:
Net Current Asset Value: $0.07 (99% below median its 10-year median of 9.97)
GF Value™: $0.57 vs. price of $0.38 (33.5% below fair value)
Industry Position: 98.8% below the Drug Manufacturers median (#288 of 608)
No single metric tells the full story. See the ELTP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Elite Pharmaceuticals Inc is a pharmaceutical company. It is principally engaged in the development and manufacture of oral, controlled-release products, using proprietary know-how and technology. The company's operating segment includes Abbreviated New Drug Applications (ANDA) and New Drug Applications (NDA). It generates maximum revenue from the ANDA segment. The company focuses on developing pain management products; manufacturing a line of generic pharmaceutical products with approved Abbreviated New Drug Applications; developing additional generic pharmaceutical products; development of other products in its pipeline including the products with its partners; and commercialization of new products.
60GF Score
Get the complete analysis for ELTP
Net Current Asset Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELTP has been successfully added to your 
